ClinicalTrials.gg
CompletedNCT00989079Updated May 29, 2020

A Single Escalating Dose Study Of Ertugliflozin (PF-04971729, MK-8835) Under Fed and Fasted Conditons In Healthy Volunteers (MK-8835-036)

A Phase 1 interventional study of Ertugliflozin and Placebo to Ertugliflozin in Type 2 Diabetes Mellitus, sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-05-29.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 28 studies testing ertugliflozin in Diabetes Mellitus, Type 2 — 3 open to participants now, 3 under way, none of them phase 3. ertugliflozin · Diabetes Mellitus, Type 2.

Enrollment
23rd of 28
24 · median 83
Started
2009
the only one that year
Phase 1
8 of 28
none open now
Registered
1st of 28
by date
Lead sponsor
18 of 28
Merck Sharp & Dohme LLC

Among the 28 studies testing ertugliflozin in Diabetes Mellitus, Type 2, this one is the 23rd largest by enrollment, is the only one that started in 2009, is one of 8 in phase 1, and was the 1st registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

3 of the 28 studies testing ertugliflozin in Diabetes Mellitus, Type 2 are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About ertugliflozin

ertugliflozin: first FDA approval 2017 (STEGLATRO), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 28 studies testing ertugliflozin in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

Ertugliflozin (PF-04971729, MK-8835) is a new compound proposed for the treatment of Type 2 diabetes mellitus. The primary purpose of this study is to evaluate the safety and tolerability along with the pharmacokinetics of single escalating doses of ertugliflozin under fed and fasted conditions in healthy volunteers.

03

Conditions studied

  • Type 2 Diabetes Mellitus

Keywords

  • Single Ascending Dose Study in healthy subjects
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy male and/or female subjects of non .
  • (BMI) of 17.5 to 30.5 kg/m2; and a total body weight >50 kg

Exclusion criteria

Exclusion Criteria:

  • Evidence or history of hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at time of dosing)
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Investigator)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    Cohort 1 Sequence 1

    Period 1 (fasted) Placebo → Period 2 (fasted) ertugliflozin (E) 10 mg → Period 3 (fasted) E 100 mg → Period 4 (fed) E 100 mg. Each dose of study drug will be separated by a minimum of 7 days.

    Drug: Ertugliflozin · Drug: Placebo to Ertugliflozin

  • Experimental
    Cohort 1 Sequence 2

    Period 1 (fasted) E 0.5 mg → Period 2 (fasted) Placebo → Period 3 (fasted) E 100 mg → Period 4 (fed) E 100 mg. Each dose of study drug will be separated by a minimum of 7 days.

    Drug: Ertugliflozin · Drug: Placebo to Ertugliflozin

  • Experimental
    Cohort 1 Sequence 3

    Period 1 (fasted) E 0.5 mg → Period 2 (fasted) E 10 mg → Period 3 (fasted) Placebo → Period 4 (fed) E 100 mg. Each dose of study drug will be separated by a minimum of 7 days.

    Drug: Ertugliflozin · Drug: Placebo to Ertugliflozin

  • Experimental
    Cohort 2 Sequence 1

    Period 1 (fasted) Placebo → Period 2 (fasted) E 30 mg → Period 3 (fasted) E 300 mg. Each dose of study drug will be separated by a minimum of 7 days.

    Drug: Ertugliflozin · Drug: Placebo to Ertugliflozin

  • Experimental
    Cohort 2 Sequence 2

    Period 1 (fasted) E 2.5 mg → Period 2 (fasted) Placebo → Period 3 (fasted) E 300 mg. Each dose of study drug will be separated by a minimum of 7 days.

    Drug: Ertugliflozin · Drug: Placebo to Ertugliflozin

  • Experimental
    Cohort 2 Sequence 3

    Period 1 (fasted) E 2.5 mg → Period 2 (fasted) E 30 mg → Period 3 (fasted) Placebo. Each dose of study drug will be separated by a minimum of 7 days.

    Drug: Ertugliflozin · Drug: Placebo to Ertugliflozin

Interventions

  • Ertugliflozin will be administered as an extemporaneously prepared suspension/solution for all doses within the initially planned range.

  • DrugPlacebo to Ertugliflozin

    Correspondingly placebo doses to ertugliflozin will be administered as suspension/solution

06

What researchers measure

Primary outcomes

  1. Number of Participants Experiencing an Adverse Event (AE)

    Time frame: Up to Day 10 of each dosing period

  2. Number of Participants Discontinuing Study Drug Due to an AE

    Time frame: Up to Day 8 of each dosing period

  3. Change from baseline in 24-hour urinary glucose excretion

    Time frame: Baseline and 24 hours

  4. Area under the plasma concentration-time curve (AUC) from Time 0 to infinity (AUCinf) for ertugliflozin

    Time frame: Up to Day 4 of each treatment period

  5. Area under the plasma concentration-time curve (AUC) from Time 0 to time of the last quantifiable concentration (AUClast) for ertugliflozin

    Time frame: Up to Day 4 of each treatment period

  6. Maximum plasma concentration (Cmax) of ertugliflozin

    Time frame: Up to Day 4 of each treatment period

  7. Time taken to reach the maximum observed plasma concentration (Tmax) of ertugliflozin

    Time frame: Up to Day 4 of each treatment period

  8. Ertugliflozin half life (t1/2)

    Time frame: Up to Day 4 of each treatment period

  9. Apparent clearance (CL/F) after a single dose of ertugliflozin

    Time frame: Up to Day 4 of each treatment period

  10. Apparent volume of distribution (Vz/F)

    Time frame: Up to Day 4 of each treatment period

Secondary outcomes

  1. Urinary glucose excretion over 72 hours

    Time frame: Up to 72 hours of each dosing period

  2. Change from baseline in 24-hour weighted mean glucose

    Time frame: Baseline and 24 hours

  3. Inhibition of glucose reabsorption

    Time frame: Up to 24 hours of each dosing period

  4. Renal clearance (CLr) of Ertugliflozin

    Time frame: Up to 24 hours of each dosing period

  5. Urinary recovery of Ertugliflozin

    Time frame: Up to 24 hours of each dosing period

07

Study locations

No study locations are listed for this record.

08

References and documents

Publications

  • Fediuk DJ, Nucci G, Dawra VK, Cutler DL, Amin NB, Terra SG, Boyd RA, Krishna R, Sahasrabudhe V. Overview of the Clinical Pharmacology of Ertugliflozin, a Novel Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor. Clin Pharmacokinet. 2020 Aug;59(8):949-965. doi: 10.1007/s40262-020-00875-1. PubMed 32337660 ↗
  • Fediuk DJ, Sahasrabudhe V, Dawra VK, Zhou S, Sweeney K. Population Pharmacokinetic Analyses of Ertugliflozin in Select Ethnic Populations. Clin Pharmacol Drug Dev. 2021 Nov;10(11):1297-1306. doi: 10.1002/cpdd.970. Epub 2021 Jul 2. PubMed 34213819 ↗
  • Marshall JC, Liang Y, Sahasrabudhe V, Tensfeldt T, Fediuk DJ, Zhou S, Krishna R, Dawra VK, Wood LS, Sweeney K. Meta-Analysis of Noncompartmental Pharmacokinetic Parameters of Ertugliflozin to Evaluate Dose Proportionality and UGT1A9 Polymorphism Effect on Exposure. J Clin Pharmacol. 2021 Sep;61(9):1220-1231. doi: 10.1002/jcph.1866. Epub 2021 Jun 19. PubMed 33813736 ↗
  • Callegari E, Lin J, Tse S, Goosen TC, Sahasrabudhe V. Physiologically-Based Pharmacokinetic Modeling of the Drug-Drug Interaction of the UGT Substrate Ertugliflozin Following Co-Administration with the UGT Inhibitor Mefenamic Acid. CPT Pharmacometrics Syst Pharmacol. 2021 Feb;10(2):127-136. doi: 10.1002/psp4.12581. Epub 2020 Dec 30. PubMed 33314761 ↗

Individual participant data

Plan to share: Yes — http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · engagezone.msd.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2009 to primary completion in Dec 2009, 1 month.

Of 453 industry-sponsored phase 1 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 5 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 11. This study's 1 month is below that.

Counting every sponsor, half of 515 studies reached it within 6 months; a quarter within 2 and three quarters within 14.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 1, 2009
First posted
Oct 2, 2009
StartActual
Oct 16, 2009
Primary completionActual
Dec 11, 2009
CompletionActual
Dec 11, 2009
Last update
May 29, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 29, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00989079
Collaborators
Pfizer
Responsible party
Sponsor
First posted
Oct 2, 2009
Start date
Oct 16, 2009
Primary completion
Dec 11, 2009
Completion
Dec 11, 2009
Last update
May 29, 2020

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ertugliflozin

Start the discussion